AVXL Oct 2024 8.000 put
| Previous close | 2.2900 |
| Open | 2.2500 |
| Bid | 2.6500 |
| Ask | 4.4000 |
| Strike | 8.00 |
| Expiry date | 2024-10-18 |
| Day's range | 2.2500 - 2.2900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GuruFocus.comAnavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
Anavex Life Sciences Corp (AVXL) reports a robust cash runway and significant progress in Alzheimer's treatment, despite facing regulatory and trial challenges.
Simply Wall St.Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
We feel now is a pretty good time to analyse Anavex Life Sciences Corp.'s ( NASDAQ:AVXL ) business as it appears the...
GlobeNewswireAnavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of
